Home Applications 217389 Application 217389
Type NDA
Sponsor MSD Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 OHTUVAYRE ENSIFENTRINE SUSPENSION;INHALATION 3MG/2.5ML Yes Yes
Source provenance: Browse the complete Orange Book source catalog · source snapshot 44 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N217389-001 OHTUVAYRE ENSIFENTRINE 3MG/2.5ML SUSPENSION / INHALATION RLD, RS 2024-06-26
Orange Book patents# Current patent rows page 1 of 1 · 5 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N217389-001 9062047 2031-08-21 U-3962 Drug substance 2024-07-12 N217389-001 10945950 2035-09-15 Drug product 2024-07-12 N217389-001 9956171 2035-09-15 U-3962 Drug product 2024-07-12 N217389-001 12409180 2043-02-20 Drug product 2025-10-07 N217389-001 12251384 2044-06-25 Drug product 2025-03-26
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 1 matching rows.
Application-product, Exclusivity code, Expiration table Application-product Exclusivity code Expiration N217389-001 NCE 2029-06-26
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-10-15 13:18:30 2026-09 N217389-001 OHTUVAYRE 3MG/2.5ML SUSPENSION / INHALATION RLD, RS 2024-06-26 c2088c7a36db…2026-09-14 22:38:34 2026-08 N217389-001 OHTUVAYRE 3MG/2.5ML SUSPENSION / INHALATION RLD, RS 2024-06-26 84e616aacf4f…2026-08-18 06:07:40 2026-07 N217389-001 OHTUVAYRE 3MG/2.5ML SUSPENSION / INHALATION RLD, RS 2024-06-26 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N217389-001 OHTUVAYRE 3MG/2.5ML SUSPENSION / INHALATION RLD, RS 2024-06-26 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N217389-001 OHTUVAYRE 3MG/2.5ML SUSPENSION / INHALATION RLD, RS 2024-06-26 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N217389-001 OHTUVAYRE 3MG/2.5ML SUSPENSION / INHALATION RLD, RS 2024-06-26 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N217389-001 OHTUVAYRE 3MG/2.5ML SUSPENSION / INHALATION RLD, RS 2024-06-26 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N217389-001 OHTUVAYRE 3MG/2.5ML SUSPENSION / INHALATION RLD, RS 2024-06-26 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N217389-001 OHTUVAYRE 3MG/2.5ML SUSPENSION / INHALATION RLD, RS 2024-06-26 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N217389-001 OHTUVAYRE 3MG/2.5ML SUSPENSION / INHALATION RLD, RS 2024-06-26 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N217389-001 OHTUVAYRE 3MG/2.5ML SUSPENSION / INHALATION RLD, RS 2024-06-26 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N217389-001 OHTUVAYRE 3MG/2.5ML SUSPENSION / INHALATION RLD, RS 2024-06-26 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 N217389-001 OHTUVAYRE 3MG/2.5ML SUSPENSION / INHALATION RLD, RS 2024-06-26 d06236e962d9…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N217389-001 OHTUVAYRE 3MG/2.5ML SUSPENSION / INHALATION RLD, RS 2024-06-26 79d66fd596c7…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N217389-001 OHTUVAYRE 3MG/2.5ML SUSPENSION / INHALATION RLD, RS 2024-06-26 301d65b070ca…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N217389-001 OHTUVAYRE 3MG/2.5ML SUSPENSION / INHALATION RLD, RS 2024-06-26 a50c72e98297…
Observed Orange Book patent history# Patent history page 1 of 2 · 58 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-10-15 13:18:30 2026-09 N217389-001 9062047 2031-08-21 U-3962 Drug substance 2024-07-12 c2088c7a36db…2026-10-15 13:18:30 2026-09 N217389-001 10945950 2035-09-15 Drug product 2024-07-12 c2088c7a36db…2026-10-15 13:18:30 2026-09 N217389-001 9956171 2035-09-15 U-3962 Drug product 2024-07-12 c2088c7a36db…2026-10-15 13:18:30 2026-09 N217389-001 12409180 2043-02-20 Drug product 2025-10-07 c2088c7a36db…2026-10-15 13:18:30 2026-09 N217389-001 12251384 2044-06-25 Drug product 2025-03-26 c2088c7a36db…2026-09-14 22:38:34 2026-08 N217389-001 9062047 2031-08-21 U-3962 Drug substance 2024-07-12 84e616aacf4f…2026-09-14 22:38:34 2026-08 N217389-001 10945950 2035-09-15 Drug product 2024-07-12 84e616aacf4f…2026-09-14 22:38:34 2026-08 N217389-001 9956171 2035-09-15 U-3962 Drug product 2024-07-12 84e616aacf4f…2026-09-14 22:38:34 2026-08 N217389-001 12409180 2043-02-20 Drug product 2025-10-07 84e616aacf4f…2026-09-14 22:38:34 2026-08 N217389-001 12251384 2044-06-25 Drug product 2025-03-26 84e616aacf4f…2026-08-18 06:07:40 2026-07 N217389-001 9062047 2031-08-21 U-3962 Drug substance 2024-07-12 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N217389-001 10945950 2035-09-15 Drug product 2024-07-12 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N217389-001 9956171 2035-09-15 U-3962 Drug product 2024-07-12 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N217389-001 12409180 2043-02-20 Drug product 2025-10-07 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N217389-001 12251384 2044-06-25 Drug product 2025-03-26 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N217389-001 9062047 2031-08-21 U-3962 Drug substance 2024-07-12 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N217389-001 10945950 2035-09-15 Drug product 2024-07-12 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N217389-001 9956171 2035-09-15 U-3962 Drug product 2024-07-12 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N217389-001 12409180 2043-02-20 Drug product 2025-10-07 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N217389-001 12251384 2044-06-25 Drug product 2025-03-26 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N217389-001 9062047 2031-08-21 U-3962 Drug substance 2024-07-12 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N217389-001 10945950 2035-09-15 Drug product 2024-07-12 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N217389-001 9956171 2035-09-15 U-3962 Drug product 2024-07-12 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N217389-001 12409180 2043-02-20 Drug product 2025-10-07 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N217389-001 12251384 2044-06-25 Drug product 2025-03-26 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N217389-001 9062047 2031-08-21 U-3962 Drug substance 2024-07-12 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N217389-001 10945950 2035-09-15 Drug product 2024-07-12 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N217389-001 9956171 2035-09-15 U-3962 Drug product 2024-07-12 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N217389-001 12251384 2044-06-25 Drug product 2025-03-26 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N217389-001 9062047 2031-08-21 U-3962 Drug substance 2024-07-12 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N217389-001 10945950 2035-09-15 Drug product 2024-07-12 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N217389-001 9956171 2035-09-15 U-3962 Drug product 2024-07-12 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N217389-001 9062047 2031-08-21 U-3962 Drug substance 2024-07-12 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N217389-001 10945950 2035-09-15 Drug product 2024-07-12 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N217389-001 9956171 2035-09-15 U-3962 Drug product 2024-07-12 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N217389-001 9062047 2031-08-21 U-3962 Drug substance 2024-07-12 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N217389-001 10945950 2035-09-15 Drug product 2024-07-12 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N217389-001 9956171 2035-09-15 U-3962 Drug product 2024-07-12 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N217389-001 9062047 2031-08-21 U-3962 Drug substance 2024-07-12 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N217389-001 10945950 2035-09-15 Drug product 2024-07-12 2680178bc6a6…
Observed Orange Book exclusivity history# Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
Documents# Document, Submission type, Date table Document Submission type Date 79127 ORIG 2024-07-22 78913 ORIG 2024-06-28 78916 ORIG 2024-06-27